Therefore, longitudinal studies to validate the value of IL-17A as a biomarker of RT-induced tissue inflammation and RITIs are needed, which will ultimately improve the therapeutic response and clinical outcomes in patients with cancer undergoing RT. The gene discussed is IL17A; the disease is cancer.